RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.
The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.
Shares of RenovoRx were up more than 4% in early morning trade.
Price: 1.16, Change: +0.05, Percent Change: +4.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。